JP3987575B2 - 標的細胞毒性アントラサイクリン類似体 - Google Patents

標的細胞毒性アントラサイクリン類似体 Download PDF

Info

Publication number
JP3987575B2
JP3987575B2 JP52012397A JP52012397A JP3987575B2 JP 3987575 B2 JP3987575 B2 JP 3987575B2 JP 52012397 A JP52012397 A JP 52012397A JP 52012397 A JP52012397 A JP 52012397A JP 3987575 B2 JP3987575 B2 JP 3987575B2
Authority
JP
Japan
Prior art keywords
formula
doxorubicin
group
compound according
dox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP52012397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000502055A (ja
JP2000502055A5 (enExample
Inventor
ヴイ シャリー アンドリュー
エー ナギー アッティラ
カイ レン―ジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3987575(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tulane University filed Critical Tulane University
Publication of JP2000502055A publication Critical patent/JP2000502055A/ja
Publication of JP2000502055A5 publication Critical patent/JP2000502055A5/ja
Application granted granted Critical
Publication of JP3987575B2 publication Critical patent/JP3987575B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP52012397A 1995-11-27 1996-11-14 標的細胞毒性アントラサイクリン類似体 Expired - Lifetime JP3987575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
US08/562,652 1995-11-27
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006309698A Division JP4778405B2 (ja) 1995-11-27 2006-11-15 標的細胞毒性アントラサイクリン類似体の合成方法

Publications (3)

Publication Number Publication Date
JP2000502055A JP2000502055A (ja) 2000-02-22
JP2000502055A5 JP2000502055A5 (enExample) 2004-09-16
JP3987575B2 true JP3987575B2 (ja) 2007-10-10

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52012397A Expired - Lifetime JP3987575B2 (ja) 1995-11-27 1996-11-14 標的細胞毒性アントラサイクリン類似体
JP2006309698A Expired - Lifetime JP4778405B2 (ja) 1995-11-27 2006-11-15 標的細胞毒性アントラサイクリン類似体の合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006309698A Expired - Lifetime JP4778405B2 (ja) 1995-11-27 2006-11-15 標的細胞毒性アントラサイクリン類似体の合成方法

Country Status (27)

Country Link
US (2) US5843903A (enExample)
EP (2) EP1384710B1 (enExample)
JP (2) JP3987575B2 (enExample)
KR (2) KR100467899B1 (enExample)
CN (2) CN1137136C (enExample)
AT (2) ATE401305T1 (enExample)
AU (1) AU709539B2 (enExample)
BR (1) BR9611647B1 (enExample)
CA (2) CA2238574C (enExample)
CZ (1) CZ297297B6 (enExample)
DE (2) DE69637604D1 (enExample)
DK (2) DK1384710T3 (enExample)
EA (1) EA001372B1 (enExample)
ES (2) ES2310222T3 (enExample)
HK (1) HK1052920B (enExample)
HU (1) HU229870B1 (enExample)
IL (3) IL119691A (enExample)
IS (2) IS2178B (enExample)
MX (1) MX9804119A (enExample)
NO (2) NO324035B1 (enExample)
NZ (1) NZ322054A (enExample)
PL (3) PL191781B1 (enExample)
PT (2) PT1384710E (enExample)
SK (2) SK284672B6 (enExample)
UA (1) UA67722C2 (enExample)
WO (1) WO1997019954A1 (enExample)
ZA (1) ZA969709B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
IL142869A0 (en) 1998-11-13 2002-03-10 Cyclacel Ltd Transport vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CA2388844A1 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP1452543A3 (en) * 2000-04-26 2005-08-03 BioSynthema, Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
IL160993A0 (en) * 2001-09-21 2004-08-31 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2003074551A2 (en) 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20040043052A1 (en) 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
DE60325240D1 (de) 2002-09-26 2009-01-22 Angiotech Int Ag Perivaskuläre hüllen
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
RU2361876C2 (ru) * 2003-04-22 2009-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Пептидные векторы
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
US20080132458A1 (en) * 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
WO2009099741A1 (en) * 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
AU2009235897B2 (en) * 2008-04-11 2012-04-12 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
MX2011000509A (es) 2008-07-15 2011-04-05 Genentech Inc Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales.
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
CA3118743A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
EP0434960B1 (en) * 1989-12-19 1996-09-18 PHARMACIA S.p.A. Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ES2075244T3 (es) * 1990-04-06 1995-10-01 Univ Tulane Analogos de la somatostatina.
DE69112684T2 (de) * 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
CZ135798A3 (cs) 1998-10-14
IS2634B (is) 2010-06-15
IL134685A0 (en) 2001-04-30
JP2000502055A (ja) 2000-02-22
KR20040037176A (ko) 2004-05-04
NO20051111L (no) 2005-03-01
BR9611647B1 (pt) 2010-03-09
CA2471775A1 (en) 1997-06-05
CZ297297B6 (cs) 2006-11-15
ES2205067T3 (es) 2004-05-01
SK284392B6 (sk) 2005-03-04
CN1137136C (zh) 2004-02-04
ATE401305T1 (de) 2008-08-15
HUP9903771A2 (hu) 2000-02-28
HU229870B1 (en) 2014-10-28
IS8567A (is) 2006-11-09
SK62898A3 (en) 1999-06-11
PL326865A1 (en) 1998-10-26
US5843903A (en) 1998-12-01
PL187230B1 (pl) 2004-06-30
CN1166597C (zh) 2004-09-15
IL134685A (en) 2002-12-01
EA001372B1 (ru) 2001-02-26
IS2178B (is) 2006-12-15
AU709539B2 (en) 1999-09-02
DK0863917T3 (da) 2004-01-19
BR9611647A (pt) 1999-02-23
JP4778405B2 (ja) 2011-09-21
JP2007045845A (ja) 2007-02-22
KR100445754B1 (ko) 2004-12-08
CA2238574A1 (en) 1997-06-05
PT863917E (pt) 2004-02-27
DK1384710T3 (da) 2008-11-17
EP1384710A1 (en) 2004-01-28
HK1052920B (zh) 2005-03-04
HK1052920A1 (en) 2003-10-03
HUP9903771A3 (en) 2000-07-28
NO982252L (no) 1998-05-15
CN1202903A (zh) 1998-12-23
DE69637604D1 (de) 2008-08-28
ZA969709B (en) 1997-08-25
CA2238574C (en) 2004-10-19
DE69630233T2 (de) 2004-08-05
ATE251179T1 (de) 2003-10-15
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
NO982252D0 (no) 1998-05-15
CN1405127A (zh) 2003-03-26
EA199800492A1 (ru) 1998-12-24
IS4734A (is) 1998-05-05
KR19990071672A (ko) 1999-09-27
UA67722C2 (en) 2004-07-15
HK1017363A1 (en) 1999-11-19
US6184374B1 (en) 2001-02-06
EP0863917B1 (en) 2003-10-01
NZ322054A (en) 1999-04-29
IL119691A0 (en) 1997-02-18
PL191781B1 (pl) 2006-07-31
ES2310222T3 (es) 2009-01-01
AU7572296A (en) 1997-06-19
IL119691A (en) 2002-02-10
NO324035B1 (no) 2007-07-30
WO1997019954A1 (en) 1997-06-05
PL188786B1 (pl) 2005-04-29
CA2471775C (en) 2008-01-29
EP0863917A1 (en) 1998-09-16
PT1384710E (pt) 2008-10-08
DE69630233D1 (de) 2003-11-06
SK284672B6 (sk) 2005-08-04
EP1384710B1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
JP3987575B2 (ja) 標的細胞毒性アントラサイクリン類似体
Janaky et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
JPH05505630A (ja) Ｌｈｒｈ拮抗薬
KR20020002482A (ko) 개선된 용해도 특성을 가진 신규의 ｌｈｒｈ 길항제
HU208159B (en) Process for producing 1h-rh analogs and pharmaceutical compositions comprising same
CA2167834A1 (en) N-terminus modified analogs of lhrh
AU748507B2 (en) Novel synthetic reaction and targeted cytotoxic anthracycline analogs obtained thereby
UA76474C2 (en) Method for conversion of nitrogen of primary aminogroup - or --hydroxy of primary amine into nitrogen of monounsaturated compound
HK1017363B (en) Targeted cytotoxic anthracycline analogs

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070713

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100720

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110720

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110720

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120720

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120720

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130720

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term